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Whilst cross-talk between stroma and epithelium is critical for tissue development and
homeostasis, aberrant paracrine stimulation can result in neoplastic transformation.
Chronic stimulation of epithelial cells with paracrine Fibroblast Growth Factor 10 (FGF10)
has been implicated in multiple cancers, including breast, prostate and pancreatic
ductal adenocarcinoma. Here, we examine the mechanisms underlying FGF10-induced
tumourigenesis and explore novel approaches to target FGF10 signaling in cancer.
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INTRODUCTION
The majority of secreted FGFs signal in an autocrine or paracrine manner, by binding to FGF
receptors (FGFR1-4) on the surface of target cells. Alternative splicing of the immunoglobin-like
domain III in FGFR1-FGFR3 produces two variants, IIIb and IIIc, which confer different ligand
binding specificities. FGF10, a member of the FGF7 subfamily, signals in a paracrine manner
through activation of the IIIb splice variants of FGFR2 (FGFR2b) and FGFR1 (FGFR1b), which
are predominantly expressed on the surface of cells of epithelial origin. Whilst in vitro assays
have shown FGF10 to activate FGFR1b more weakly than FGFR2b, FGFR1b activation in vivo
may be achieved in scenarios where extracellular FGF10 reaches high concentrations (Zhang et al.,
2006; Ornitz and Itoh, 2015). It has been suggested that FGF10 may also perform intracrine roles
within FGF10-producing cells, primarily through trafficking to the nucleus. Whilst the functional
significance of FGF10 nuclear localization remains to be determined, disrupted nuclear localization
of FGF10 has been linked to lacrimo-auriculo-denot-digital syndrome (Mikolajczak et al., 2016).
FGF10 is known to be critical for brain, lung and limb development (Sekine et al., 1999;
Hajihosseini et al., 2008) and contributes to wound healing and tissue repair by promoting cell
migration and proliferation (Werner et al., 1994; Volckaert et al., 2011). Given this role of FGF10
in adult tissues, it is unsurprising that aberrant signaling of FGF10 through FGFR2b, and in some
instances FGFR1b, contributes to the progression of a number of human cancers.
FGF10 IN BREAST CANCER
Studies in Fgf10−/− and Fgfr2b−/− mouse embryos demonstrate that FGF10-FGFR2b
signaling plays a key role in mammary gland development (Mailleux et al., 2002; Veltmaat
et al., 2006). Whilst FGF10 is not expressed in the luminal epithelial cells of the normal
human breast duct (Grigoriadis et al., 2006), transcription of the FGF10 gene is elevated
Frontiers in Genetics | www.frontiersin.org 1 October 2018 | Volume 9 | Article 499
fgene-09-00499 October 22, 2018 Time: 14:34 # 2
Clayton and Grose Roles of FGF10 in Cancer
10% of breast carcinomas (Theodorou et al., 2004) and genome-
wide association studies have identified variants near the FGF10
locus as a genetic risk factor for breast cancer susceptibility
(Stacey et al., 2008). Similarly, SNPs affecting FGFR2b expression
have been correlated with breast cancer susceptibility (Meyer
et al., 2008; Fachal and Dunning, 2015) and amplification of
FGFR1, occurring in up to 12% of breast cancer cases (Cerami
et al., 2012; Gao et al., 2013; Pereira et al., 2016), is correlated with
poor prognosis (Reis-Filho et al., 2006; Elbauomy Elsheikh et al.,
2007). A number of in vitro studies have shed light on the cellular
roles of FGF10-FGFR2/1 signaling in breast cancer cell behavior
(Figure 1).
FGFR2 activation has been shown to repress the activity of
the estrogen receptor (ER) regulon (Campbell T. M. et al., 2016),
which has been correlated with poor prognosis in a cohort of
ER+ breast cancer patients (Castro et al., 2016). Stimulation of
the ER+ breast cancer cell line MCF-7 with FGF10 enhanced
the interaction of the transcription factors NFIB and YBX1
with the ER, which inhibited its transcriptional activity and
shunted the cells toward a more ER−, basal-like cancer phenotype
with reduced estrogen dependency and lower sensitivity to anti-
estrogen therapy. Treatment of ER+ breast cancer cell lines with
the FGFR inhibitors AZD4547 and PD173074 sensitized the cells
to the anti-estrogen tamoxifen, suggesting that targeting FGF10-
FGFR2 signaling may offer a new approach to overcoming
resistance to hormone-deprivation therapy in ER+ breast cancer
(Campbell et al., 2018).
Nuclear localization of receptor tyrosine kinases (RTKs) has
been documented for 12 RTK families (Chen and Hung, 2015)
and has been correlated with poor prognosis in various cancers
(Aleksic et al., 2010; Hadžisejdic´ et al., 2010; Traynor et al., 2013;
Coleman et al., 2014). In vitro studies using breast cancer cell lines
showed that FGF10 stimulation lead to the nuclear translocation
of a 55 kDa C-terminal fragment of FGFR1, which in turn
promoted the transcription of genes that stimulate cell migration
and invasion. Cleavage of FGFR1 to yield this C-terminal
fragment was found to be mediated by granzyme B activity,
which was itself positively regulated by FGF10 stimulation. In 3D
organotypic cell culture models, FGFR1 nuclear localization was
most apparent in invading cells. Importantly, increased nuclear
FGFR1 staining was also detected in tissue sections of invasive
breast carcinoma (Chioni and Grose, 2012).
Analysis of FGFR2b signaling networks in vitro revealed
that stimulation of FGFR2b with FGF10 promoted receptor
recycling and led to an increase in breast cancer migration,
whilst stimulation of FGFR2b with FGF7 resulted in receptor
degradation and led to increased cell proliferation. Using
quantitative proteomics to explore the mechanism underlying
this functional dichotomy, it was revealed that FGF10 binding
resulted in the novel phosphorylation of FGFR2b at Y734,
FIGURE 1 | Model depicting molecular mechanisms through which FGF10-FGFR1 and FGF10-FGFR2 signaling may contribute to breast cancer progression.
Binding of FGF10 to FGFR2b leads to phosphorylation of the receptor at Y734 and recruitment of PI3K and SH3BP4, which promote receptor recycling and
increased cell migration. FGF10 binding to FGFR1 leads to cleavage of the receptor by granzyme B and the translocation of a 55 kDa fragment of FGFR1 to the
nucleus, leading to increased cell migration. Stimulation of ER+ breast cancer cells with FGF10 enhances the interaction of NFIB and YBX1 with the ER and inhibits
its transcriptional activity to produce a more ER− phenotype with lower sensitivity to anti-estrogen therapy. PI3K, phosphatidylinositide 3-kinase; SH3BP4,
SH3-binding protein 4; CTSC, cathepsin C; GrB, granzyme B; NFIB, nuclear factor I B; YBX1, Y-Box Binding Protein-1; ERα, estrogen receptor α.
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which led to the recruitment of PI3K and SH3BP4 and
targeting of the receptor to recycling endosomes. Whilst the
mechanism through which FGFR2b recycling promotes cell
migration is not fully understood, the role of FGFR2b-PI3K-
SH3BP4 complex formation in this response to FGF10 was
illustrated by experiments showing that FGF10-stimulated cell
migration could be inhibited by depletion of SH3BP4 or
expression of a FGFR2b-Y734F mutant (Francavilla et al.,
2013).
FGF10 IN PROSTATE CANCER
In vivo models have shown that elevated paracrine FGF10
stimulation of mouse prostate epithelial cells led to the
development of adenocarcinoma, predominantly via activation
of epithelial FGFR1. These lesions showed heightened levels of
androgen receptor (AR), caused most likely by post-translational
modifications augmenting AR stability. Following host
castration, a subset of FGF10-induced prostate adenocarcinoma
cells showed continued survival and proliferation, suggesting that
paracrine FGF10 stimulation may contribute to the development
of androgen independence in this murine model of prostate
cancer (Memarzadeh et al., 2007). Later work using testicular
feminized mice revealed that FGF10-induced prostate neoplasia
is dependent on the expression of functional AR (Memarzadeh
et al., 2011), demonstrating a role for FGF10-AR cross-talk in
early prostate tumourigenesis.
AR expression has also been detected in prostate cancer-
associated fibroblasts (CAFs) in vitro and siRNA-mediated
depletion of AR from these stromal cells resulted in a decrease in
FGF10 expression. Thus, there may exist a positive feedback loop
whereby increased stromal cell AR levels promote the expression
of FGF10, which then acts in a paracrine manner to elevate
AR levels in prostate epithelial cells and potentially also in an
autocrine manner to further elevate levels of AR in the stroma
(Figure 2; Yu et al., 2013).
In a model of FGF10-induced prostate tumourigenesis,
enhanced phosphorylation of Src-family kinases (SFKs) was
detected in the adenocarcinoma lesions. Prostate epithelium
from Src−/−Fyn+/− mice showed normal histology following
exposure to elevated paracrine FGF10, suggesting that the
tumourigenic effects of FGF10 on prostate epithelial cells
are in part mediated by epithelial Src and Fyn kinases.
Importantly, this work also established a link between FGF10,
SFK signaling and AR levels by demonstrating that FGF10-
stimulated Src−/−Fyn+/− xenografts showed downregulation of
AR relative to FGF10-stimulated wild type xenografts (Cai et al.,
2011). Recent in vivo studies have provided further evidence
for a role of a FGF10/FGFR/Src signaling axis in prostate
cancer. Ectopic expression of FGFR1, FGFR2, or Src in mouse
prostate epithelial cells growing in a normal microenvironment
was not sufficient to induce prostate tumourigenesis in vivo.
However, paracrine FGF10 was found to synergize with FGFR1/2
over-expression to induce epithelial-mesenchymal transition and
FGF10 synergized with Src overexpression to induce high-grade
epithelial tumors. Importantly, inhibition of Src signaling, either
by pharmacological Src kinase inhibitors or by deletion of the Src
myristoylation site, inhibited paracrine FGF10-induced prostate
tumourigenesis (Li et al., 2018b).
Whilst these studies in mouse models of prostate cancer have
revealed potential novel roles for FGF10 in androgen signaling, it
is important to note that elevated FGF10 has not been detected
in human prostate cancer tissue (Abate-Shen and Shen, 2007;
Eiro et al., 2017) and levels of FGF10 in the normal adult
prostate are extremely low, compared to those of FGF7 (Ropiquet
et al., 2000). Transfection of malignant prostate tumor cells with
FGFR2b cDNA has been shown to reduce the growth rate of the
derived tumors (Feng et al., 1997) and restoration of FGFR2b
expression in castration-resistant prostate cancer cells increased
sensitivity to chemotherapeutic agents (Shoji et al., 2014). Further
investigation is therefore required to fully elucidate the complex
roles of FGF10-FGFR2b signaling in prostate tumourigenesis.
FGF10 IN PANCREATIC CANCER
Whilst FGF10 expression is not detected in the normal adult
human pancreas (Ishiwata et al., 1998), FGF10 is required for
the proliferation of pancreatic epithelial progenitor cells and
FGF10−/− mouse embryos show pancreatic hypoplasia, arrested
pancreatic epithelial branching and an absence of islet cells
(Bhushan et al., 2001). Expression of FGFR2 and FGFR1 are up-
regulated in approximately 25% of pancreatic adenocarcinoma
(PDAC) cases and elevated stromal FGF10 expression coupled
with high cancer cell FGFR2b expression has been correlated
with poor prognosis (Cerami et al., 2012; Gao et al., 2013; Bailey
et al., 2016). In vitro studies using FGFR2b-expressing pancreatic
cancer cell lines revealed that FGF10 stimulation promoted
cancer cell migration and invasion through the up-regulation of
MT1-MMP and TGF-β1 (Figure 2; Nomura et al., 2008).
More recent work aiming to identify diagnostic and predictive
markers for pancreatic cancer found that FGF10 levels were
elevated in the sera of untreated patients with PDAC compared
to healthy controls and found that in combination with a panel
of 4 other cytokine markers, FGF10 could be used as a diagnostic
biomarker for PDAC (Torres et al., 2014).
FGF10 IN STOMACH CANCER
During development, FGF10 signaling plays a key role in stomach
morphogenesis, through regulating gastric gland formation
and maintaining an epithelial progenitor cell niche (Nyeng
et al., 2007). In a cohort of 961 gastric cancers from the
United Kingdom, Korea and China, FGFR2 amplification was
detected in 4.2–7.4% of cases and was associated with lymph
node metastasis and poor overall survival (Su et al., 2014).
FGF10 amplification has also been detected in 3% of gastric
cancers (Ooi et al., 2015) and immunohistochemical analysis
of 178 gastric adenocarcinoma samples revealed that FGF10
levels are correlated with poor prognosis (Sun et al., 2015).
Interrogation of most recent cBioPortal data suggests this could
be an underestimate, with FGF10 amplifications reported in 5.7%
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FIGURE 2 | Mechanisms underlying tumor-promoting functions of FGF10 in human cancers. Blue, prostate cancer; orange, pancreatic ductal adenocarcinoma;
green, cutaneous squamous cell carcinoma; pink, breast cancer; black, lung cancer; CAF, cancer-associated fibroblast; TAM, tumor-associated macrophage.
of stomach adenocarcinoma cases (Cerami et al., 2012; Gao et al.,
2013).
FGF10 IN SKIN CANCER
Whilst local elevation of FGF22, FGF7, and FGF10 are required
for efficient healing of skin lesions (Braun et al., 2004),
sustained elevation of FGF10 has also been implicated in
cutaneous squamous cell carcinoma (SCC). Epidermal deletion
of the tumor suppressor Pten produces a model of cutaneous
squamous cell carcinoma in mice (Suzuki et al., 2003). The
epidermis of these mice showed elevated keratinocyte expression
of FGF10, with no change in levels of FGF7, FGF2, and
FGF1. This increase in FGF10 was not accompanied by any
Fgf10 transcriptional changes and was found to be dependent
on the elevated mTORC1 signaling resulting from loss of
the negative regulator, PTEN. The specific contribution of
FGF10 to carcinogenesis was demonstrated by induction of
constitutive epidermal FGF10 expression, which produced
epidermal hyperplasia and spontaneous papillomas in all mice
by 3 weeks of age. Crucially, it was shown that genetic ablation
of Fgfr2 prevented hyperplasia in PTEN-deficient epidermis,
suggesting that epidermal tumourigenesis induced by PTEN loss
is mediated by an up-regulation of FGF10-FGFR2 autocrine
signaling. Low levels of PTEN accompanied by elevated FGF10
have been observed in a panel of clinical SCC samples,
highlighting the potential importance of this mechanism in the
human disease (Hertzler-Schaefer et al., 2014).
In contrast to these data implicating FGF10 in skin
carcinogenesis, previous work has suggested that FGF10-FGFR2b
signaling may perform tumor-suppressive functions in the skin.
Mice lacking epidermal Fgfr2b showed increased sensitivity
to chemical carcinogens and 10% of animals surviving into
adulthood developed spontaneous papillomas. Epidermal Fgfr2b
ablation induced several changes in gene expression in the
skin, including downregulation of Serpin a3b, a potential tumor
suppressor (Grose et al., 2007).
FGF10 IN LUNG CANCER
Whilst FGF10 is crucial for branching morphogenesis in the
developing lung (Sekine et al., 1999), induction of FGF10
over-expression in the respiratory epithelial cells of adult mice
has been shown to cause multifocal pulmonary adenomas
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(Clark et al., 2001). A recent study designed to identify
genomic variations in cell-free DNA in small cell lung
cancer patients identified FGF10 amplification in 37.5% and
of patients tested and FGFR1 amplification in 25% of cases
(Du et al., 2018). Analysis of 1144 lung cancer tumors
comprising lung adenocarcinomas and lung squamous cell
carcinomas revealed FGF10 amplifications in 8.7% and FGFR1
amplifications in 9.3% of cases (Campbell J. D. et al.,
2016).
The role of FGF10 in lung cancer initiation and
progression remains poorly understood. However, emerging
evidence suggests that FGF10 secreted from tumor-associated
macrophages may play a role in promoting lung tumourigenesis
(Figure 2). Tumour-associated macrophages (TAMs) are
macrophages that have been co-opted by the tumor
microenvironment to promote the growth and invasion of
cancer cells (Noy and Pollard, 2014). Recent work showed that
induction of FGF9 overexpression in the lungs of transgenic
mice resulted in the development of adenocarcinoma-like
nodules that are infiltrated with an immune response consisting
mostly of macrophages. Expression analysis revealed that
the TAMs from these transgenic mice expressed significantly
higher levels of FGF2, FGF10, and FGFR2 than macrophages
from wild-type mice. It has been suggested that activation
of an FGF10-FGFR2 pathway may underlie the transition to
FGF9-independent tumor growth, which has been observed in
previous studies using this lung cancer model (Hegab et al.,
2018). Expression profiling of TAMs in other pre-clinical
cancer models will reveal the clinical significance of these early
findings.
THERAPEUTIC APPROACHES
TARGETING FGF10-FGFR2 SIGNALING
In light of mounting evidence supporting a role for aberrant
FGF10-FGFR2b signaling in tumourigenesis, FGFR2b has
become an attractive therapeutic target. Whilst a number of
pan-FGFR inhibitors have entered the clinic (Clayton et al.,
2017), the development FGFR2-specific inhibitors is hindered
by the structural similarity of the kinase domains of FGFR1-3
(Belov and Mohammadi, 2013). For this reason, ATP-mimetic
inhibitors of the FGFR2b isoform are currently unavailable.
However, the development of monocloncal antibodies targeting
FGFR2b may provide an opportunity to target this isoform
specifically. Bemarituzumab (2018) (FPA144) is an anti-
FGFR2b humanized monoclonal antibody currently in Phase
I clinical trials as a monotherapy for FGFR2b-amplified
gastric cancers. Bemarituzumab prevents the binding of
FGF10, FGF7 and FGF22 to the FGFR2b and is reported to
also promote antibody-dependent cell-mediated cytotoxicity
through the recruitment of natural killer cells to the tumor
(Bemarituzumab (FPA144) | Gastric Cancer | Five Prime
Therapeutics).
FGF10 signal transduction requires recruitment of the
myristoylated scaffold protein FRS2α to the activated receptor,
and recent pre-clinical work has highlighted the potential of
targeting FRS2α myristoylation in paracrine FGF10-induced
tumourigenesis. Primary mouse prostate cells transduced
with FRS2α(wt) or FRS2α(G2A), a mutant that cannot be
myristolyated, were mixed with mouse urogenital sinus
mesenchyme (UGSM) cells expressing either FGF10 or GFP
as a control. The cells were implanted sub-renally into
SCID mice. Xenografts derived from FRS2α(wt) prostate
cells mixed with FGF10-UGSM showed adenocarcinoma,
whilst xenografts of FRS2α(G2A) cells with FGF10-UGSM
cells showed normal prostate tubules. In vitro work showed
that FRS2α myristolylation can be targeted pharmacologically
by treating with the myristoyl-coA analog B13 (Li et al.,
2018a).
Recent evidence has demonstrated that a FGF10/FGFR/Src
signaling axis may contribute to prostate tumourigenesis via
a mechanism that is dependent on Src activity. Inhibition
of Src myristoylation, and therefore membrane localization,
has been suggested as a viable therapeutic strategy for these
prostate cancer subtypes. In vitro studies showed that loss of
Src myristoylaton had a significant inhibitory effect on FGF10-
induced oncogenic signaling in comparison with a kinase-dead
Src mutant (Li et al., 2018b). These data have prompted efforts
to develop an N-myristoyltransferase inhibitor as a means to
therapeutically target the FGF10/FGFR/Src signaling axis in
cancer (French et al., 2004; Thinon et al., 2014; Kim et al.,
2017).
CONCLUSION AND FUTURE
PERSPECTIVES
The receptors for FGF10, FGFR2, and FGFR1 have been
implicated in several human cancers, including pancreatic ductal
adenocarcinoma and gastric cancer. However, since FGFR2 and
FGFR1 are activated by a number of FGF family members, it
has been difficult to attribute the tumor-promoting effects of
these receptors to binding of a specific ligand. Recent data have
begun to shed light on the role of FGF10 in these cancers,
demonstrating that paracrine FGF10 synergizes with FGFR1/2
over-expression to induce epithelial-mesenchymal transition in
a pre-clinical model of prostate cancer. The development of
isoform-selective pharmacological tools will clarify the role of
FGF10-FGFR2b/1b signaling in different cancer types and will
allow the potential of FGF10 as a therapeutic target to be
explored.
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